CAR-modified T-cell therapy for cancer: an updated review Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • The use of chimeric antigen receptor (CAR)-modified T cells is a promising approach for cancer immunotherapy. These genetically modified receptors contain an antigen-binding moiety, a hinge region, a transmembrane domain, and an intracellular costimulatory domain resulting in T-cell activation subsequent to antigen binding. Optimal tumor removal through CAR-modified T cells requires suitable target antigen selection, co-stimulatory signaling domain, and the ability of CAR T cells to traffic, persist, and retain antitumor function after adoptive transfer. There are several elements which can improve antitumor function of CAR T cells, including signaling, conditioning chemotherapy and irradiation, tumor burden of the disease, T-cell phenotype, and supplementary cytokine usage. This review outlines four generations of CAR. The pre-clinical and clinical studies showed that this technique has a great potential for treatment of solid and hematological malignancies. The main purpose of the current review is to focus on the pre-clinical and clinical developments of CAR-based immunotherapy.


  • Haji-Fatahaliha, Mostafa
  • Hosseini, Morteza
  • Akbarian, Asiye
  • Sadreddini, Sanam
  • Jadidi-Niaragh, Farhad
  • Yousefi, Mehdi

publication date

  • August 17, 2016